Regular aspirin use may slow progression of early emphysema
2015-05-17
(Press-News.org) ATS 2015, DENVER -- Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
"Other than smoking cessation and avoidance, there are no known methods for reducing the risk of developing emphysema," said researcher Carrie Aaron MD, of the Columbia University Medical Center in New York. "In our large general population sample, we found that regular aspirin use (three or more days per week) was associated with a slower progression of percent emphysema on computed tomography (CT) scans over 10 years."
The study, which was motivated by findings of pulmonary vascular involvement in emphysema and the importance of platelet function in other vascular diseases, included 4,471 individuals participating in the Multi-Ethnic Study of Atherosclerosis Lung Study. The percentage of lung volume with emphysematous features (percent emphysema) was assessed on up to 4 CT scans performed over approximately 10 years of follow-up. Spirometry, a measure of expiratory airflow, was performed in 81% of study subjects.
Of the 4,471 study subjects, 21% (921) used aspirin regularly, 55% were ever-smokers, and 25% of those with spirometry had results indicating airflow obstruction. Regular aspirin use was associated with a significantly slower progression of percent emphysema over ten years, when compared to those who did not use aspirin, even after adjustment for a number of potential confounding factors, including age, sex, race/ethnicity, cigarettes/day, pack-years, and hypertension. Results were consistent in propensity score analyses, performed to minimize effects of confounding by indication. Similar reductions in the rate of progression of percent emphysema were seen among ever-smokers, and greater reductions were observed among individuals with spirometric evidence of airflow obstruction.
"Our study found that persons taking aspirin regularly had a slower progression of emphysema over 10 years compared to those who did not, and that this difference was not explained by many factors that we believe affect progression of emphysema." said Dr. Aaron. "The findings might suggest that regular aspirin use may slow the progression of subclinical emphysema, perhaps through effects on platelet activation or inflammation."
INFORMATION:
* Please note that numbers in this release may differ slightly from those in the abstract. Many of these investigations are ongoing; the release represents the most up-to-date data available at press time.
Abstract 69159
Aspirin Use and Longitudinal Progression of Percent Emphysema on CT: The MESA Lung Study
Type:
Late Breaking Abstract
Category:
06.03 - COPD: Epidemiology (CP/EOPH)
Authors:
C.P. Aaron1, J.E. Schwartz1, E.A. Hoffman2, R. Tracy3, J.H.M. Austin4, L.J. Smith5, D.R. Jacobs6, K.E. Watson7, R.G. Barr1;1Columbia University - New York, NY/US, 2University of Iowa - Iowa City, IA/US, 3University of Vermont - Colchester, VT/US,4Columbia University - New York/US, 5Northwestern University - Chicago, IL/US, 6University of Minnesota - Minneapolis, MN/US,7UCLA - Los Angeles, CA/US
Abstract Body
Rationale: Emphysema on computed tomography (CT) is associated with increased morbidity and mortality in the general population without airflow limitation and in COPD; however, there are no preventive strategies except smoking avoidance. The pulmonary vasculature has been implicated in emphysema, and platelets are involved in many vascular diseases. Aspirin reduces platelet activation; however, there is limited information on aspirin use and change in emphysema. We hypothesized that aspirin use would be associated with slower progression of percent emphysema on CT.
Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) enrolled participants 45-84 years old without clinical cardiovascular disease in 2000-02. Medications were ascertained by medication inventory; regular use of aspirin was considered if reported use was 3 or more days/week. The MESA Lung Study assessed percent emphysema below -950 Hounsfield units on lung fields of cardiac CTs at baseline and 1-2 follow-up examinations, and on full-lung CTs at the 10-year follow-up examination. At approximately 5 years after baseline, 80% underwent pre-bronchodilator spirometry. Mixed effect models evaluated the association of baseline aspirin use with longitudinal change in percent emphysema after adjustment for age, sex, race/ethnicity, height, weight, education, cigarettes/day, pack-years, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker use, hypertension, C-reactive protein, plasma sphingomyelin, CT scanner model and mAs (radiation) dose. Secondary analyses used a propensity score approach with inverse probability of treatment weighting.
Results: At baseline the 4372 participants were mean age 61±10 years, 49% male, 53% ever-smokers, and 20% (890) used aspirin regularly. FEV1/FVC was below 0.7 for 25% (863) with spirometry. Median baseline percent emphysema was 2.92 (IQR 1.22, 5.77) and mean increase was 0.83%/10 years (95% CI: 0.53, 1.12; P-value END
ELSE PRESS RELEASES FROM THIS DATE:
2015-05-17
A relatively new, easier to implement, and better-tolerated method to provide supplemental oxygen to patients at risk of respiratory failure after surgery did not result in a worse rate of treatment failure compared to a more commonly used method, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American Thoracic Society 2015 International Conference.
After cardiothoracic surgery, acute respiratory failure is common and associated with an increased risk of illness and death. When low-flow oxygen therapy is insufficient ...
2015-05-17
ATS 2015, DENVER -- Unlike standard cigarettes, the components of electronic cigarettes are not regulated and standardized, thus they vary widely between products. The characteristics of these e-cigarette elements, including their delivery systems, combustion apparatuses, and the composition of the nicotine solutions they contain may affect the levels of potentially hazardous substances in the vapor they produce, according to a new study presented at the 2015 American Thoracic Society International Conference.
"While the chemical compositions and negative health effects ...
2015-05-17
ATS 2015, DENVER -- With just one exposure to electronic-cigarette (e-cigarette) vapor, participants in a study of 30 healthy subjects demonstrated a diminishment of cough reflex sensitivity. The study was presented at the 2015 American Thoracic Society International Conference.
"Although e-cigarettes have become popular worldwide, very little is known about their effect on the respiratory system. There has been no other research to our knowledge on the effect of e-cigarette use on the sensitivity of the cough reflex," said lead author Peter Dicpinigaitis, MD, Professor ...
2015-05-17
ATS 2015, DENVER -- Certain flavorings used in electronic cigarette liquid may alter important cellular functions in lung tissue, according to new research presented at the 2015 American Thoracic Society International Conference. These changes in cell viability, cell proliferation, and calcium signaling are flavor-dependent. Coupling these results with chemicals identified in each flavor could prove useful in identifying flavors or chemical constituents that produce adverse effects in users.
"The effects of the various chemical components of e-cigarette vapor on lung tissue ...
2015-05-17
ATS 2015, DENVER - There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference.
"While e-cigarettes have been shown to significantly improve abstinence at 1 month compared with placebo, no such evidence is available supporting their effectiveness for longer periods," said lead author Riyad al-Lehebi, MBBS, of the University of Toronto. "Until such data are available, there are ...
2015-05-17
Chicago, Illinois, May 17, 2015 -- Treatment with two medications that target the most common genetic cause of cystic fibrosis improves lung function and lowers the rate of pulmonary exacerbations, according to the results from a Phase III international clinical trial published online in the New England Journal of Medicine on May 17, 2015. Combined lumacaftor-ivacaftor therapy was shown to be safe and effective for cystic fibrosis patients with two copies of the cystic fibrosis gene mutation (F508del) found in nearly half of the patients with this disease.
"These groundbreaking ...
2015-05-17
ATS 2015, DENVER - In recent years and months, peanut allergies in children have been in the news frequently, as scientists reveal new insights into why more and more children are developing them and what can be done to avoid them. However, until now, few have studied the connection between peanut allergy and childhood asthma.
A new study has shown that many children who have asthma have a sensitivity to peanuts, but did not know it. Conducted by researchers in the U.S., the study specifically looked at pediatric asthma patients at a pediatric pulmonary clinic.
The ...
2015-05-17
ATS 2015, DENVER--Lung transplant candidates who are about 5'3" or shorter have longer waiting times than taller candidates and are more likely to die within a year while waiting for a lung transplant, according to a study presented at the 2015 American Thoracic Society International Conference.
Shorter adults are also more likely to be placed on mechanical ventilation while they wait for lung transplantation, said lead author Jessica Sell, MPH, of the Columbia University Medical Center in New York.
The researchers retrospectively reviewed information from 13,341 adults ...
2015-05-17
ATS 2015, DENVER -- Caucasian and Hispanic children who undergo lung transplantation appear to be at greater risk for developing chronic kidney disease, or CKD, according to a small retrospective study conducted at Texas Children's Hospital.
The study, believed to be the first to look at CKD in children who have received lung transplants, also found that those children with high levels of tacrolimus, a powerful immunosuppressant given to fight organ rejection, circulating in the blood and those who experience at least one episode of acute kidney injury during their recovery ...
2015-05-17
Washington, DC (May 17, 2015) -- While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released today at Digestive Disease Week® (DDW) 2015. These savings would have a significant economic impact on society.
The higher cure rate and lessened side-effects of treating patients with an all-oral ...
LAST 30 PRESS RELEASES:
[Press-News.org] Regular aspirin use may slow progression of early emphysema
